AbbVie Is Considering Ending Its $51B Shire Deal

The transcript discusses the implications of tax inversion deals, focusing on Shire's valuation and potential as a takeover target. It highlights market reactions to legislative changes in the US and the challenges in pricing risks associated with such deals. The discussion also covers the responsibilities of company boards in appraising new situations and the likelihood of future deals proceeding.

What are the potential benefits of a tax inversion deal for a company?

How does the market react to changes in tax legislation regarding tax inversions?

What factors might influence whether a company like Shire remains a takeover target?

Discuss the implications of the board's fiduciary duty in the context of a tax inversion deal.

What challenges do companies face when trying to recover from a significant market event?